Back To Top

You have matched to 1 trial

Guest Profile:  No profile selected

Copy link
Sort by zip code: 94107 Hide Map Icon
mail-icon

Register to sign up for Trial Alerts

Receive emails about new trials that match your profile.
1

N17350 for Advanced Triple Negative (ER-, PR-, HER2-) Breast Cancer

A Phase 1/2 Open-Label, Dose Finding and Expansion Study to Investigate the Safety and Effectiveness and Determination of the Optimal Dose of N17350 Administered Intratumorally in Participants With Advanced Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of N17350, an investigational drug given by injection directly into a tumor. N17350 is designed to kill a wide range of cancer cells while preserving and activating the immune system so the body can recognize and attack the cancer.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer whose cancer has progressed after standard treatment, who cannot tolerate standard treatment, or who have no standard treatment options available. You must have at least one tumor that can be safely reached with a needle for injection. This trial is also enrolling people with other types of cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">N17350, by injection, 1 time every 2 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem"> N17350 is a lab made version of an enzyme called elastase. It is injected straight into a tumor rather than given through the whole body. It is designed to selectively kill cancer cells and, at the same time, activate the immune system so it can mount a lasting response against the cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07339176' target='_blank'>ClinicalTrials.gov</a> </li></ul>
1

N17350 for Advanced Triple Negative (ER-, PR-, HER2-) Breast Cancer

A Phase 1/2 Open-Label, Dose Finding and Expansion Study to Investigate the Safety and Effectiveness and Determination of the Optimal Dose of N17350 Administered Intratumorally in Participants With Advanced Solid Tumors
Icon

Nearest Location from 94107:
1643 miles
The University of Texas MD Anderson Cancer Center
Houston, TX

Icon

Visits:
About 1 visit every 2 weeks during treatment

Icon

ClinicalTrials.gov: NCT07339176

Icon

Phase I-II

HELP GUIDE